An off-the-shelf immunotherapy for targeting solid tumors: Ready-to-use CAR-NKT cells show promise
A UCLA research team has identified the best design for a promising new type of immunotherapy that could be mass-produced to treat multiple solid tumors. The study focused on engineered invariant natural killer T cells, or ...
Feb 4, 2026
0
30









